Detalles de la búsqueda
1.
Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy.
Ann Rheum Dis
; 81(3): e52, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32188691
2.
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Ann Rheum Dis
; 76(10): 1747-1750, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600350
3.
Myocarditis with Immune Checkpoint Blockade.
N Engl J Med
; 376(3): 290-1, 2017 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28102662
4.
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.
Ann Rheum Dis
; 78(7): e67, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29858173
5.
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.
Ann Rheum Dis
; 77(3): 468-470, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28242618
6.
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.
Eur J Cancer
; 178: 49-59, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403367
7.
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Cancer Treat Rev
; 110: 102452, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998515
8.
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Eur J Cancer
; 158: 217-224, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34627664
9.
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae.
Brain Commun
; 3(4): fcab220, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34651126
10.
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Clin Cancer Res
; 27(2): 492-503, 2021 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32887723
11.
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Eur J Cancer
; 158: 208-216, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452793
12.
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
Eur J Cancer
; 156: 46-59, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34425404
13.
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
Drug Saf
; 43(2): 111-117, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31630381
14.
Infectious complications in patients treated with immune checkpoint inhibitors.
Eur J Cancer
; 141: 137-142, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33137589
15.
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Eur J Cancer
; 129: 71-79, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32143106
16.
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.
Eur J Cancer
; 130: 39-50, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32172197
17.
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
Am J Ophthalmol
; 202: 109-117, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772350
18.
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
JAMA Oncol
; 5(9): 1310-1317, 2019 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31169866
19.
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
J Immunother Cancer
; 7(1): 337, 2019 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31796119
20.
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Lancet Haematol
; 6(1): e48-e57, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30528137